149 related articles for article (PubMed ID: 21918608)
1. A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.
Ohyashiki JH; Hamamura R; Kobayashi C; Zhang Y; Ohyashiki K
Adv Appl Bioinform Chem; 2008; 1():85-98. PubMed ID: 21918608
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
[TBL] [Abstract][Full Text] [Related]
3. Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells.
Hamamura RS; Ohyashiki JH; Kurashina R; Kobayashi C; Zhang Y; Takaku T; Ohyashiki K
Br J Cancer; 2007 Oct; 97(8):1099-105. PubMed ID: 17895889
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
5. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Pise-Masison CA; Radonovich M; Dohoney K; Morris JC; O'Mahony D; Lee MJ; Trepel J; Waldmann TA; Janik JE; Brady JN
Blood; 2009 Apr; 113(17):4016-26. PubMed ID: 19131553
[TBL] [Abstract][Full Text] [Related]
7. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
9. SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.
Nian Q; Xiao Q; Wang L; Luo J; Chen LP; Yang ZS; Liu L
Int J Mol Med; 2014 Apr; 33(4):856-62. PubMed ID: 24535175
[TBL] [Abstract][Full Text] [Related]
10. Secreted protein acidic and rich in cysteine functions in colitis via IL17A regulation in mucosal CD4
Tanaka M; Takagi T; Naito Y; Uchiyama K; Hotta Y; Toyokawa Y; Ushiroda C; Hirai Y; Aoi W; Higashimura Y; Mizushima K; Okayama T; Katada K; Kamada K; Ishikawa T; Handa O; Itoh Y
J Gastroenterol Hepatol; 2018 Mar; 33(3):671-680. PubMed ID: 28582593
[TBL] [Abstract][Full Text] [Related]
11. Secreted protein acidic and rich in cysteine (SPARC) induces apoptosis of human brain vascular smooth muscle cells through regulating HK2 in intracranial aneurysm.
Zhou D; Li T; Tan X; Yun C; Jiang P; Zhang T; Kuang H; Wang Y
Front Mol Neurosci; 2023; 16():1290556. PubMed ID: 38076208
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
14. Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
Zhang Y; Zhu X; Hou K; Zhao J; Han Z; Zhang X
Oncol Rep; 2015 May; 33(5):2277-84. PubMed ID: 25812695
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
Engür S; Dikmen M; Öztürk Y
Immunopharmacol Immunotoxicol; 2016; 38(2):87-97. PubMed ID: 26667773
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
Kuroda K; Liu H
Int J Oncol; 2019 Apr; 54(4):1357-1366. PubMed ID: 30720063
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of noncaspase proteases, calpain and proteasome, via ALLN and Bortezomib contributes to cell death through low degradation of pro-/anti-apoptotic proteins and apoptosis induction.
Hamidi R; Ataei F; Hosseinkhani S
Med Oncol; 2022 Jun; 39(9):125. PubMed ID: 35716322
[TBL] [Abstract][Full Text] [Related]
18. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise.
Aoi W; Naito Y; Takagi T; Tanimura Y; Takanami Y; Kawai Y; Sakuma K; Hang LP; Mizushima K; Hirai Y; Koyama R; Wada S; Higashi A; Kokura S; Ichikawa H; Yoshikawa T
Gut; 2013 Jun; 62(6):882-9. PubMed ID: 22851666
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095
[TBL] [Abstract][Full Text] [Related]
20. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
